Narsoplimab

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 20/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)

Conditions

Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)

Trial Timeline

— → —

NCT ID

NCT04247906

About Narsoplimab

Narsoplimab is a pre-clinical stage product being developed by Omeros Corporation for Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA). The current trial status is completed. This product is registered under clinical trial identifier NCT04247906. Target conditions include Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA).

What happened to similar drugs?

1 of 3 similar drugs in Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA) were approved

Approved (1) Terminated (1) Active (1)

✅ICL670NovartisApproved

❌Efprezimod alfa + Placebo + Methotrexate + TacrolimusMerckPhase 3

🔄SAR302503 + PlaceboBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04247906	Pre-clinical	Completed	—	—	Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)

Competing Products

20 competing products in Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)

See all competitors

Product	Company	Stage	Hype Score
ASP0113	Astellas Pharma	Phase 2	35
Itacitinib + Corticosteroid	Johnson & Johnson	Phase 2	27
Imipenem/Cilastatin/Relebactam + Cefepime + Meropenem + Piperacillin-Tazobactam + Vancomycin + Daptomycin + Linezolid	Merck	Phase 2	35
caspofungin + liposomal amphotericin B	Merck	Phase 2	35
Efprezimod alfa + Placebo + Methotrexate + Tacrolimus	Merck	Phase 3	32
Dabrafenib Mesylate + Trametinib Dimethyl Sulfoxide + Uprosertib	Novartis	Phase 1/2	32
ICL670	Novartis	Approved	43
Blinatumomab + Dexamethasone + Ibrutinib + Nivolumab	Amgen	Phase 2	27
Denosumab	Amgen	Phase 2	35
Remdesivir	Gilead Sciences	Phase 2	42
Inotuzumab Ozogamicin + Vincristine Sulfate Liposome	Pfizer	Phase 1/2	24
SAR302503	Bristol Myers Squibb	Phase 2	35
SAR302503 + Placebo	Bristol Myers Squibb	Phase 3	40
SAR302503	Bristol Myers Squibb	Phase 2	35
SAR302503	Bristol Myers Squibb	Phase 2	35
SARS-CoV-2 mRNA Vaccine ARCT-021 + Tozinameran	Arcturus Therapeutics	Phase 2	32
Vancomycin Pre-Treatment + Vancomycin Placebo + SER-155 + SER-155 Placebo	Seres Therapeutics	Phase 1	19
BL-8040 + Placebo	BioLineRx	Phase 1	19
Recombinant Interferon Alfa-2b + Rintatolimod	AIM ImmunoTech	Phase 1/2	14
human lactoferrin peptide 1-11	AM-Pharma	Phase 1/2	22